ABVC BioPharma

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FREMONT, CA, April 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that all five clinical study sites in Taiwan participating in the Phase II, part 2 clinical study of the company's ADHD medicine have completed their site initiation visits (SIV).

ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study

FREMONT, CA, April 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire  – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the principal investigators of the Phase II clinical study of Vitargus® will hold a virtual meeting on April 27, 2022. The meeting will be attended by all principal investigators currently selected from the Australian and Thailand sites to help coordinate the study, entitled “A Prospective Multi-Site Open Label Randomized Controlled Clinical Investigation of the Safety and Effectiveness of ABV-1701 Ocular Endotamponade (OE).”

ABVC BioPharma Announces Vitargus Phase II Clinical Study Investigator Meeting

FREMONT, CA, March 31, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver high efficacy with low toxicity for improved health outcomes, today announced its financial and operating results for the fiscal year ended December 31, 2021.

ABVC Biopharma Announces Fiscal Year 2021 Financial and Operational Results

Fremont, CA, March 23, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the company will be participating at the Maxim Group 2022 Virtual Growth Conference, taking place March 28-30, 2022.

ABVC BioPharma to Present at the Maxim Group 2022 Virtual Growth Conference

Fremont, CA, Feb. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Principal Investigator Meeting for the ABV-1505 Phase II Part 2 ADHD clinical study will be held on February 14, 2022. Principal investigators from the University of California San Francisco (“UCSF”) Medical Center and five prestigious Taiwan medical centers, including National Taiwan University Hospital, Taipei Veterans General Hospital, Linkou Chang Gung Memorial Hospital, Kaohsiung Chang Gung Memorial Hospital and Cheng Hsin General Hospital, will virtually participate in the meeting to discuss potential further improvement to the study protocol prior to initiation.

ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study

Thailand Sites Join Australian Sites Confirmed to Participate in the Study

ABVC BioPharma Selects Additional Vitargus® Phase II Study Sites

Fremont, CA, Dec. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vitargus®, the world's first bio-degradable vitreous substitute, was presented by Dr. Andrew Chang, MD, Ph.D on December 11, 2021 at the 14th Asia-Pacific Vitreo-Retina Society (“APVRS”) Congress. APVRS, one of the most prestigious ophthalmology conferences in the Asia-Pacific region, attracts over 800 leading vitreoretinal specialists from around the world. Dr. Chang, the Medical Director of Sydney Retina Clinic and Head of the Retinal Unit at the Sydney Eye Hospital, is the principal investigator of Vitargus Phase I first-in-human clinical study.

ABVC BioPharma's Vitreous Substitute Vitargus Presented at 14th APVRS Congress

Fremont, CA, Dec. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vitargus®, its vitreous substitute intended to facilitate retina re-attachment surgery, received the 2021 “National Innovation and Renewal of Diligence” award from the Institute for Biotechnology and Medicine Industry (IBMI) of Taiwan. The award was presented at the Taiwan Medical Technology Exhibition on December 2, 2021 at the Taipei Nangang Exhibition Center.

ABVC BioPharma Medical Device Vitargus Receives Taiwan National Innovation Award

The stock price of ABVC Biopharma Inc (NASDAQ: ABVC) increased by 5.14% in the previous trading session. This is why it happened.

ABVC Biopharma Stock (ABVC): Why The Price Increased

ABVC BioPharma Inc (NASDAQ: ABVC) shares gained during the market trading session on continued momentum from yesterday's dietary supplement distribution deal and after a favorable report from Zacks Small-Cap Research. Yesterday, ABVC Biopharma announced that BioKey would produce dietary supplements derived from the maitake mushroom in tablet and liquid forms.

Why ABVC BioPharma Shares Are Trading Higher On Friday?

Fremont, CA, Dec. 09, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire --  ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that BioKey, a wholly-owned subsidiary of the Company based in Fremont, California, will produce dietary supplements derived from the maitake mushroom in both tablet and liquid forms. The maitake mushroom is rich in bioactive polysaccharides, especially beta-glucans. Beta-glucans in maitake mushrooms have been found to reduce cholesterol, resulting in improved artery functionality and overall better cardiovascular health, which tends to lower the risk of heart disease and provide immune system support. In addition, BioKey has entered into a three-year distribution agreement with Define Biotech Co. Ltd., a Taiwan-based pharmaceutical marketing company that focuses on sales of drugs, dietary supplements and medical products in the Asia-Pacific region. The agreement grants Define Biotech the exclusive right to distribute this new dietary supplement in China and Taiwan in exchange for the commitment to purchase $3.0 million worth of the new product over the three-year period.  BioKey will manufacture the supplements at its GMP manufacturing facility in Fremont, California. Further, the company entered into a contract to grow maitake mushrooms in a humid, temperature-controlled environment free of pesticides and chemicals. Although many mushroom-based supplements are available on the market today, BioKey believes this new line has significant competitive advantage given (a) the purity and consistency of the mushrooms used by BioKey surpass those used in existing maitake mushroom supplements currently on the market and (b) the extraction process BioKey employs delivers a particularly strong dose. “Although dietary supplements are not key to our strategic business model, in light of the COVID-19 pandemic, the global demand for immunity-boosting products has increased significantly,” said Dr. Howard Doong, Chief Executive Officer of ABVC BioPharma. “Taking advantage of our existing technology and manufacturing expertise, we have produced a superior immune strengthening dietary supplement product using the maitake mushroom. Based on the distribution agreement with Define Biotech alone, we expect our subsidiary in California to achieve financial profitability by the end of 2022.” Studies have shown the beta-glucans in maitake mushroom to strengthen the immune system. In a clinical trial on postmenopausal breast cancer patients, oral administration of the maitake extract demonstrated immunomodulatory effects. In addition, a separate clinical trial found maitake extracts to enhance neutrophil and monocyte function in patients with myelodysplastic syndrome, boosting production of lymphokines (protein mediators) and interleukins (secreted proteins), and demonstrated improved immune response. Further, clinical trials have shown beta-glucans to lower blood glucose levels, thereby helping to activate insulin receptors, while reducing insulin resistance in diabetes management. The global dietary supplements market size was valued at $140.3 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 8.6% from 2021 to 2028 (Grand View Research, February 2021). Botanicals held the second largest share within the dietary supplement category in 2020 and are expected to witness significant growth over the forecast period. Immunity-boosting herbs witnessed a surge in demand in 2020 with a steady growth trend expected to continue for the foreseeable future. About ABVC BioPharmaABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process at world-famous research institutions (such as Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center). For Vitargus®, the company intends to conduct the clinical trials through Phase III at various locations throughout the globe.  Forward-Looking StatementsThis press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at  http://www.sec.gov . The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. ContactICR, LLC Lucy PengPhone: +1 646-677-1872Email: Lucy.Peng@icrinc.com

ABVC BioPharma Introduces Dietary Supplement Based on Maitake Mushroom, Enters into $3.0 Million Distribution Agreement

FREMONT, CA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes, today announced its financial and operating results for the third quarter of 2021.

ABVC Biopharma Reports Third Quarter 2021 Financial and Operational Results

FREMONT, CA, Nov. 11, 2021 (GLOBE NEWSWIRE) -- via  NewMediaWire -- ABVC BioPharma, Inc.(Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes, today announced the receipt of $4,245,000 in additional gross proceeds from the exercise of Series A warrants issued in the company's August 3, 2021, public offering of securities. Investors participating in ABVC's financing exercised a total of 673,723 Series A warrants at a price of $6.30 per share. Combined with the Company's underwritten public offering of 1,100,000 shares, in which the Company announced the receipt of gross proceeds of $6,875,000, the Company has received an aggregate of approximately $11,120,000 as of November 9, 2021.

ABVC Biopharma Receives Additional $4,245,000 from Exercise of Warrants, Total Capital from Public Offering Increases to Approx. $11.1M

ANI Pharma

Moderna

Sanofi

Sorrento Therapeutics Inc

Biotech stocks to note as the coronavirus pandemic rages on across the globe.

Best Biotech Stocks To Buy Now? 5 To Check Out In November 2021

Artelo Biosciences Inc

Farmmi

Check these Reddit penny stocks out for your watchlist in November The post Hot Reddit Penny Stocks to Watch That Exploded Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Reddit Penny Stocks to Watch That Exploded Today

ABVC BioPharma (ABVC) stock is rocketing higher on Monday as investors on social media hype up the shares despite a lack of news. The post ABVC Stock: The Social Media Chatter That Has ABVC BioPharma Shooting 250% Higher Today appeared first on InvestorPlace.

ABVC Stock: The Social Media Chatter That Has ABVC BioPharma Shooting 250% Higher Today

Shares of ABVC Biopharma Inc (NASDAQ: ABVC) are on fire this morning. The stock jumped nearly 300% on Monday as retail traders on StockTwits picked ABVC Biopharma as their next favourite.

ABVC Biopharma stock is up 275% on Monday: explained here

The stock price of ABVC Biopharma Inc (NASDAQ: ABVC) increased by over 300% pre-market today. This is why it happened.

ABVC Stock: Why The Price Surged Today

ABVC BioPharma Receives Taiwan Regulatory Approval for ABV-1505 ADHD Phase II Part 2 Clinical Study

Central IRB Approved for ABV-1505 Phase II Part II in Taiwan Sites

The stock price of ABVC Biopharma Inc (NASDAQ: ABVC) increased by over 25% pre-market today. This is why it happened.

ABVC Stock: Why The Price Increased Today

The stock price of ABVC Biopharma Inc (NASDAQ: ABVC) increased by over 2% during intraday trading today. This is why it happened.

ABVC Stock: Why It Increased Today

ABVC BioPharma Inc (NASDAQ: ABVC) is trading higher Wednesday after the company announced new PCT filings for major depressive disorder (MDD) and attention-deficit hyperactivity disorder (ADHD) treatments. The two PCT applications describe the treatment methods of oral administrating compositions containing Radix Polygalae extract.

Why ABVC BioPharma Shares Are Trading Higher Today

The stock price of ABVC BioPharma, Inc. (NASDAQ: ABVC) increased by over 40% pre-market. This is why it happened.

ABVC Stock: Over 40% Increase Pre-Market Explanation

FREMONT, CA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has filed new PCT (Patent Cooperation Treaty) applications in connection with its medicines that treat major depressive disorder (MDD) and Attention-Deficit Hyperactivity Disorder (ADHD). The two PCT applications describe the treatment methods of oral administrating compositions containing Radix Polygalae (Polygala tenuifolia Willd) extract (PDC-1421). PDC-1421 is the active ingredient for both the company's MDD and ADHD drugs.

ABVC BioPharma Announces New PCT Filings for MDD and ADHD Treatments

FREMONT, CA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Zacks Small Cap Research has issued an update report on the company which may be accessed at:

News for ABVC BioPharma Stock (ABVC)